Archive

Panel debate merits of transplantation

In a debate about whether autologous stem cell transplant (ASCT) is still right for all transplant eligible MM patients, the panel staked out their positions at the International… read more.

Is cure possible now for myeloma patients?

Professor Sagar Lonial (Atlanta, USA) and Professor Philippe Moreau (Nantes, France) discuss whether patients are being cured now and what the future holds.

IMW 2019: Relapsed/refractory myeloma: ongoing challenges and emerging hope

Article written by Tom Collins. Interview by Esther Drain.

Pomalidomide with bortezomib and dexamethasone is one of the best options for multiple myeloma patients who have relapsed while on lenalidomide, but other data are in the offing that could provide even more options, said Professor Philippe Moreau, head of the haematology department at University Hospital in Nantes, France.

IMW 2019: As treatment options explode, questions remain myriad in myeloma

Article written by Tom Collins. Interview by Esther Drain. Meletios Dimopoulos, MD, professor and chairman of clinical therapeutics at the University of Athens and a long-time expert in… read more.

IMW 2019: Panel debate merits of transplantation

Article written by Tom Collins. Interview by Esther Drain In a debate about whether autologous stem cell transplant (ASCT) is still right for all transplant eligible MM patients,… read more.

Relapsed/refractory myeloma: ongoing challenges and emerging hope

Pomalidomide with bortezomib and dexamethasone is one of the best options for multiple myeloma patients who have relapsed while on lenalidomide, but other data are in the offing… read more.

Sequencing and options at relapse

Professor Philippe Moreau (Nantes, France) and Professor Paul Richardson (Boston, USA) give their opinion on sequencing in myeloma and options at relapse and Dr Rakesh Popat (London, UK) highlights the real life management… read more.

Debate: RVd vs KRd in frontline

In the ‘Great Debates in MM’ session Professor Paul Richardson (Boston, USA) argued the pros and cons of RVd vs KRd in the frontline. Written by Esther Drain

Planned treatment stoppage not seen in real world practice

Many newly diagnosed patients receive multiple myeloma treatment for more than 12 months, according to data collected from treatment centers around the world, showing that the shift away… read more.

IMiDs and proteasome inhibitors- comparable results in maintenance

Progression-free survival (PFS) and overall survival (OS) were improved similarly with maintenance therapy with lenalidomide or bortezomib in two studies presented at the International Myeloma Workshop. Written by… read more.

Favourable early findings seen in older patients with comorbidities

Preliminary results from a real-world study show that patients at an older age with a high comorbidity burden had their normal activities uninterrupted when they switched to the… read more.